SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
78estimated
Sites
32
Countries
Belgium, India, Israel +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-03-04 | actual | When the study began enrolling |
| Primary completion | 2023-08-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-08 | estimated | The whole study's end, after follow-up |
| First posted | 2021-03-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity
Interventions
- Drug: Liraglutide
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFRelative change in BMI (Body mass index)
measured From baseline (week 0) to week 56
Publications
- PMID 39258838 — reports results
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed